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In this marker evaluation study, we tested whether distinct patterns of functional genomic polymorphisms in genes involved in drug
metabolic pathways and DNA repair that predict clinical outcome to 5-fluorouracil (5-FU)/oxaliplatin chemotherapy in patients with
advanced colorectal cancer could be identified. Functional polymorphisms in DNA-repair genes XPD, ERCC1, XRCC1, XPA, and
metabolising genes glutathione S-transferase GSTP1, GSTT1, GSTM1, and thymidylate synthase (TS) were assessed retrospectively in
106 patients with refractory stage IV disease who received 5-FU/oxaliplatin combination chemotherapy, using a polymerase chain
reaction-based RFLP technique. Favourable genotypes from polymorphisms in XPD-751, ERCC1-118, GSTP1-105, and TS-30-
untranslated region (30UTR) that are associated with overall survival were identified. After adjustment for performance status, the
relative risks of dying for patients who possessed the unfavourable genotype were: 3.33 for XPD-751 (P¼0.037), 3.25 for GSTP1-
105 (P¼0.072), 2.05 for ERCC1-118 (P¼0.037), and 1.65 for TS-30UTR (P¼0.091) when compared to their respective beneficial
genomic variants. Combination analysis with all four polymorphisms revealed that patients possessing X2 favourable genotypes
survived a median of 17.4 months (95% confidence interval (CI): 9.4, 26.5) compared to 5.4 months (95% CI: 4.3, 6.0) in patients with
no favourable genotype. Patients who carried one favourable genotype demonstrated intermediate survival of 10.2 months (95% CI:
6.8, 15.3; Po0.001). Polymorphisms in the TS-30UTR and GSTP1-105 gene were also associated with time to progression. After
adjustment for performance status, patients with an unfavourable TS-30UTR genotype had a relative risk of disease progression of
1.76 (P¼0.020) and those with the unfavourable GSTP1-105 genotype showed a relative risk of progression of 2.00 (P¼0.018). The
genomic polymorphisms XPD-751, ERCC1-118, GSTP1-105, and TS-30UTR may be useful in predicting overall survival and time to
progression of colorectal cancer in patients who receive 5-FU/oxaliplatin chemotherapy. These findings require independent
prospective confirmation.
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Colorectal cancer is the third most common cause of death from
cancer in the United States (ACS, 2004). Despite improved
screening methods, a significant proportion of cases are diagnosed
in the advanced stages where chemotherapy either in the adjuvant
or palliative setting is necessary. While chemotherapy has shown
clearly to improve survival, the objective responses of the various
drugs range between 10 and 50%, either as single agents or in
combination. Furthermore, the choice of optimal chemotherapy is
complicated by a wide interpatient variability of drug response and
host toxicity.
Differences in drug transport, metabolism, signalling, and
cellular response pathways, all contribute to the observed diversity
of patients’ reactions (Evans and Relling, 1999). A growing body of
evidence suggests that functional genomic polymorphisms in drug
target genes (Gebhardt et al, 1999; Lima et al, 1999), metabolising
enzymes (Ando et al, 2000), and DNA-repair enzymes (Park et al,
2001) may have important implications for drug efficacy. One of
the remaining challenges is to evaluate whether these pharmaco-
genetic variations are useful in predicting drug response, toxicity,
and survival to specific chemotherapy regimens. Therefore,
determination of significant associations between genomic poly-
morphisms and defined clinical end points (eg survival, response,
toxicity) may improve the prediction of treatment success and
thereby the tailoring of chemotherapy.
Fluoropyrimidines remain widely used in the treatment of
colorectal cancer. High levels of their target enzyme thymidylate
synthase (TS) have been repeatedly correlated with resistance to
the agent and poorer clinical outcome (Johnston et al, 1995;
Leichman et al, 1995; Aschele et al, 2002). A polymorphic 28-bp
tandem repeat polymorphism in the regulatory region of the TS
gene is associated with TS expression (Horie et al, 1995; Kawakami
et al, 1999; Kawakami et al, 2001; Pullarkat et al, 2001) and toxicity
to 5-fluorouracil (5-FU) chemotherapy (Pullarkat et al, 2001).
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also have the potential to segregate responders from nonrespon-
ders to 5-FU in both metastatic and adjuvant first-line che-
motherapies (Etienne et al, 2002; Iacopetta et al, 2001; Marsh et al,
2001; Pullarkat et al, 2001; Villafranca et al, 2001). Its predictive
value in combination and second-line chemotherapy is unknown.
Moreover, the impact of a recently identified polymorphic site in
the 30-untranslated region (30UTR) of the TS gene that may alter
gene transcription (Ulrich et al, 2000) on clinical outcome in 5-FU-
treated patients is unclear at this point.
The introduction of the platinum compound oxaliplatin in the
treatment of colorectal cancer has increased response rates up to
25% even in heavily pretreated relapsing patients when adminis-
tered in combination with 5-FU (Bleiberg, 1996). A randomised
phase III study showed superiority of oxaliplatin and 5-FU
combination therapy in refractory patients compared to either
treatment alone, in terms of response rate, time to progression,
and tumour-related symptoms (Rothenberg et al, 2003). Most
recently, oxaliplatin has been approved in the US as first- and
second-line therapy in combination with 5-FU for the treatment of
metastatic colorectal cancer. Predictive markers for clinical
outcome to this platinum agent may help to identify prospectively
those patients who are more likely to benefit from the treatment.
Resistance to platinum agents has been attributed to enhanced
tolerance to platinum DNA adducts, decreased drug accumulation,
or enhanced DNA repair (Raymond et al, 1998). Proteins of the
nucleotide excision repair (NER) pathway, in particular, are
thought to play a key role in the repair of DNA damage caused
by platinum compounds. For example, low gene expression levels
of the NER protein ERCC1 were associated with superior response
to 5-FU/cisplatin (Metzger et al, 1998) in gastric cancer and 5-FU/
oxaliplatin in colorectal cancer (Shirota et al, 2001). Additional
important players of the NER pathway include the Xeroderma
pigmentosum group A and D (XPA and XPD) genes. Relevant
genomic polymorphisms have been described in all genes of these
NER pathway participants and preliminary data support the
hypothesis that a prediction of drug response to platinum may be
possible based on the analysis of their genotypes (Yu et al, 1997;
Dybdahl et al, 1999; Butkiewicz et al, 2000; Lunn et al, 2000; Park
et al, 2001; Spitz et al, 2001).
Glutathione S-transferase P1 (GSTP1) is a member of a
superfamily of dimeric phase II metabolic enzymes that play an
important role in the cell defense system. It is involved in platinum
detoxification and is highly overexpressed in human colorectal
tumours (Moscow et al, 1989). An activity altering polymorphism
in GSTP1 has already been identified as a prognostic marker in
oxaliplatin treatment (Stoehlmacher et al, 2002). However, its
predictive value for drug response and time to progression has not
yet been demonstrated. Polymorphisms in GSTT1 and M1 genes
that affect GST activity have also been described (London et al,
2000).
In the current study, we examine a panel of 10 genetic
polymorphisms within eight genes (TS, XPD, XPA, ERCC1,
XRCC1, GSTP1, GSTM1, GSTT1) involved in the metabolism and
detoxification of 5-FU and oxaliplatin as well as genes of the DNA-
repair complex. We tested the hypothesis whether these poly-
morphisms, alone or in combination, may have the potential to
predict clinical response, time to progression, and overall survival
in advanced refractory colorectal patients treated with combina-
tion 5-FU/oxaliplatin chemotherapy.
PATIENTS AND METHODS
Subjects
Subjects included in this analysis were selected from a cohort of
patients with metastatic colorectal cancer who were enrolled and
treated on a compassionate use protocol of oxaliplatin plus 5-FU
(protocol number 3C-98-3) for patients who had previously
received chemotherapy for the treatment of the metastatic disease.
Patients’ performance status was classified according to Eastern
Cooperative Oncology Group (ECOG) Criteria (Oken et al, 1982).
Patients with an ECOG status 42 were not eligible for this study.
All patients signed an informed consent prior to entering the
study. This study was conducted at the University of Southern
California/Norris Comprehensive Cancer Center and was approved
by the Institutional Review Board of the University of Southern
California for Medical Sciences. This protocol was opened for
accrual in November 1998 and was closed in May 2001. A total of
263 patients were registered on the protocol. A blood and tissue
collection protocol to establish the clinical significance of genetic
polymorphisms in gastrointestinal cancer (OS-99-10) was opened
almost 1 year after (September 1999) the opening of the 3C-98-3
protocol. Specimens from 123 patients were available for genotypic
analysis.
Prior to the study described in this manuscript, we had studied
the XRCC1 polymorphisms in 61 patients (Stoehlmacher et al,
2001), XPD polymorphisms in 73 patients (Park et al, 2001), and
GST polymorphisms in 107 patients (Stoehlmacher et al, 2002). For
the purpose of the current study, only patients with genotypic
information in at least seven out of the 10 polymorphisms were
included. When comparing these 106 patients to the 157 patients
who were treated on the protocol, but not included in the current
report, there were no statistically significant differences in age (P-
value for w
2 test¼0.46), race (P-value for w
2 test¼0.55), or overall
survival (P-value for the log-rank test¼0.45). A higher percentage
(75%) of patients in the current report were male compared to
those (61%) who were not included (P-value for w
2 test¼0.018).
Clinical evaluation and response criteria
All patients enrolled in protocol 3C-98-3 had previously treated
advanced colorectal tumours, which had progressed following
treatment with a fluoropyrimidine-based regimen. In addition,
79% (84 of 106) of patients had also received an additional second-
line treatment with irinotecan (CPT-11). Once enrolled on study,
the majority (93%) of participants received the following
combination therapy regimen: 130mgm
 2 oxaliplatin every 3
weeks and weekly continuous infusion 5-FU (200mgm
 2day
 1);
one patient received 130mgm
 2 oxaliplatin every 3 weeks with
daily bolus 5-FU; and six patients received 85mgm
 2 oxaliplatin
every 3 weeks with weekly 5-FU.
For patients with measurable disease, responders to therapy
were classified as those patients whose tumour burden (the sum,
over all measurable lesions, of the products of the largest diameter
and its perpendicular diameter) decreased by 50% or more for at
least 6 weeks. CT imaging for response was performed every 6
weeks. For patients with evaluable but nonmeasurable disease,
responders were classified as those whose tumour and all evidence
of disease disappeared (a complete response, CR). Progressive
disease was defined as 25% or more increase in tumour burden
(compared to the smallest measurement) or the appearance of new
lesions. Patients, who did not experience a response and did not
progress within the first 12 weeks following start of 5-FU/
oxaliplatin, were classified as having stable disease.
Genotyping
Genomic DNA was extracted from 200ml whole blood using the
QiaAmp kit (Qiagen, Valencia, CA, USA). All samples were
performed using a polymerase chain reaction (PCR)–RFLP
technique. After restriction enzyme analysis PCR fragments were
visualised in a 2.5–3% agarose gel.
The assays for the polymorphisms in TS-50UTR, TS-30UTR,
GSTP1-105, GSTM1, GSTT1, XRCC1-399, XPD-751, XPD-156, and
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Arand et al, 1996; Harries et al, 1997; Yu et al, 1997; Dybdahl et al,
1999; Butkiewicz et al, 2000; Lunn et al, 2000; Ulrich et al, 2000).
Primer sequences, restriction enzymes, and references for the
analyses are given in Table 1. The PCR reaction volume was 50ml.
The protocol for simultaneous analysis of GSTT1 and GSTM1 was
modified as follows: the primers (GSTM1, GSTT1, and albumin)
were at the final concentration of 50pmol per 50ml PCR reaction,
the polymerase used was rTaq (Pharmacia, Piscataway, NJ, USA).
The PCR conditions for the ERCC1-118 assay were as follows:
951C for 5min; 40 cycles of 951C for 1min, annealing at 651C for
1min, 721C for 1min; and then 721C for 7min. The RFLP analysis
of the resultant 208-bp fragment led to C/C (208bp), C/T (208, 128,
80bp), and T/T (128, 80bp) genotypes.
Statistical analysis
Initially, objective tumour response, time to progression, and
overall survival were the end points considered in this analysis.
Reliable toxicity data were not available in this retrospective study.
Owing to the fact that in this series only nine of 101 patients who
were evaluable for tumour response experienced an objective
tumour response to chemotherapy, no further analysis of tumour
response and its association with genetic polymorphisms was
undertaken. Survival was calculated from the time that a patient
started treatment until the last follow-up or death from any cause;
patients who were alive at the last follow-up were censored at that
time. Time to progression was calculated from the time that a
patient started treatment until taken off study due to disease
progression. Patients who were taken off study or who died prior
to progression were censored at the time that they were taken off
study. The log-rank test (Miller, 1981) and Kaplan–Meier plots
(Kaplan and Meier, 1958) were used to evaluate the association of
overall survival and time to progression with each of the following
baseline prognostic factors: histology (well or moderate vs poor
differentiation), side of tumour (right vs left), number of
metastatic sites (1, 2, 3, or more), performance status (ECOG 0
or 1 vs 2), ethnicity (Caucasian, Hispanic, Black, and Asian), age at
enrollment of study (p50, 51–60, and 460 years), and gender.
The association of each polymorphism with survival and time to
progression was analysed singly using Kaplan–Meier plots, the
log-rank test, the relative risk ratio, and its associated 95%
confidence interval (CI) (Pike, 1972; Bernstein et al, 1981)were
calculated. Contingency tables and Fisher’s exact test (Metha and
Patel, 1983) were used for the categorical variables to evaluate the
association of the polymorphism and baseline data and the
response to chemotherapy. Statistical Analysis Systems (SAS),
version 8.2 (SAS Institute, Cary, NC, USA), Epilog (Epicenter,
Pasadena, CA, USA) software were used for the analyses.
In the initial univariate survival analyses, ECOG performance
status was the only clinical variable significantly associated (at the
0.05 level) with clinical outcome (survival and time to progres-
sion). Therefore, for the multivariate analyses, ECOG performance
status was included as a stratification variable.
An internal validation analysis using bootstrapping was
performed to evaluate the choice of variables selected in the final
multivariate model. First, 500 bootstrap samples were generated
from the original sample. Each bootstrap sample consisted of 106
observations drawn from the original data set using simple
random sampling with replacement (Altman and Andersen,
1989). Second, univariate survival analysis (the log-rank test)
was conducted for each of seven baseline prognostic factors and
each of 10 genomic polymorphisms in each of the 500 bootstrap
samples. The percentage of selection of variables for multivariable
Table 1 Primer sequences and restriction enzymes
Gene Primers Restriction enzyme Polymorphism (localisation) Significance Reference
GSTP1-105
[F] 50-ACCCCAGGGCTCTATGGGAA-30 Ile-Val Activity k Harries et al
[R] 50-TGAGGGCACAAGAAGCCCCT-30 BsmAI (Exon 5)
GSTM1
[F] 50-GAACTCCCTGAAAAGCTAAAGC-30 Deletion Activity abolished Arand et al
[R] 50-GTTGGGCTCAAATATACGGTGG-30 —
GSTT1
[F] 50-TTCCTTACTGGTCCTCACATCTC-30 — Deletion Activity abolished Arand et al
[R] 50-TCACCGGATCATGGCCAGCA-30
XRCC1-399
[F] 50-TTGTGCTTTCTCTGTGTCCA-30 Arg-Gln DNA-repair Lunn et al
[R] 50-TCCTCCAGCCTTTTCTGATA-30 MspI (Exon 10) activity k
TS-50
[F] 50-GTGGCTCCTGCGTTTCCCCC-30 28bp repeat Change of expression Horie et al
[R] 50-GCTCCGAGCCGGCCACAG-GCATGGCGCGG-30 (50-region)
—
TS-30UTR
[F] 50-CAAATCTGAGGGAGCTGAGT-30 6bp deletion Unknown Ulrich et al
[R] 50-CAGATAAGTGGCAGTACAGA-30 DraI (3-UTR)
XPD-751
[F] 50-CCTCTCCCTTTCCTCTGTTC-30 Lys-Gln DNA repair Lunn et al
[R] 50-CAGGTGAGGGGGACATCT-30 MboII (Exon 23) Cancer risk
XPD-156
[F] 50-TGGAGTGCTATGGCACGATCTCT-30 C-A Association with Dybdahl et al
[R] 50-CCATGGGCATCAAATTCCTGGGA-30 TfiI (Exon 6) cancer risk
XPA-50
[F] 50-TCAGAAAGGCCGCTGGGT-30 A-G Unknown Butkiewicz et al
[R] 50-CATATCACCCCATTGTGAATG-30 MspI( 5 0-region)
ERCC1-118
[F] 50-GCAGAGCTCACCTGAGGAAC-30 C-T ?Change of Yu et al
[R] 50-GAGGTGCAAGAAGAGGTGGA-30 BsrDI (Exon 118) expression
TS¼thymidylate synthase; UTR¼untranslated region; GSTP¼glutathione S-transferase.
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The variables that were selected by more than half of the analyses
of the bootstrap samples were entered in the final model (Chen and
George, 1985; Altman and Andersen, 1989).
It should be noted that in this evaluation study consisting of 106
patients and 66 events, the possibility also exists that moderate
patterns and associations (e.g. relative risks of 1.5–2.0) may not
result in ‘statistically significant’ trends. For that reason, Table 4
has been presented in its entirety, with results for all 10
polymorphisms studied.
RESULTS
Patients
A total of 106 patients, consisting of 79 men (75%) and 27 women
(25%) with a median age of 60 years (range: 24–84 years), were
evaluated in this study. There were 75 (71%) Caucasians, 14 (13%)
Hispanics, 11 (10%) Asians, and six (6%) African-American study
participants. The genotype assays XPD-751, ERCC1-118, and
GSTP1-105 were successful for 106 patients. Results from the
remaining assays could be obtained as follows: XRCC1-399 and
TS-50UTR: 105 patients; XPD-156: 103 patients; TS-30UTR, GSTT1,
and GSTM1: 102 patients; and XPA-50 93 patients.
Of particular interest was the distribution of the polymorphisms
within the four racial/ethnic subgroups of patients included in this
series. Of the 10 sets of polymorphism studies, three (XPD-751,
ERCC1-118, and TS-30UTR) had distributions that varied across
the four racial/ethnic subgroups (Table 2). No clear patterns for
significant associations between any of these polymorphisms and
any of the other demographic (gender), clinical (performance
status, localisation of the tumour, and number of metastases),
or pathological characteristics (tumour differentiation) were
observed. Of these 50 comparisons, the following four associations
Table 2 Association of genomic polymorphisms with ethnicity
Ethnicity
Caucasian Hispanic Black Asian
Factors No. of patients N % N% N % N % P-value*
XPD-751 o0.001
Lys/Lys 40 19 25 8 57 4 67% 10 91
Lys/Gln 53 46 61 4 29 2 33% 1 9
Gln/Gln 13 11 14 2 14 0 0% 0 0
XPD-156 0.14
A/A 14 12 16 1 8 0 0% 1 9
C/A 59 43 58 7 54 1 17% 8 73
C/C 30 19 26 5 38 5 83% 2 18
Unknown 3 2 1
XPA-50 0.14
G/G 24 18 27 4 33 3 60% 0 0
A/G 53 37 56 7 58 2 40% 7 64
A/A 16 11 17 1 8 0 0% 4 36
Unknown 13 10 2 1
ERCC1-118 0.002
C/C 30 15 20 6 43 6 100 4 36
C/T 45 34 45 5 36 0 0 6 55
T/T 31 27 36 3 21 0 0 1 9
XRCC1-399 0.63
Arg/Arg 44 29 39 5 36 3 50 7 64
Gln/Arg 51 39 52 8 57 2 33 3 27
Gln/Gln 10 7 9 1 7 1 20 1 9
Unknown 1 1
TS-30UTR 0.030
+6BP/+6BP 37 31 42 4 31 1 17 1 9
+6BP/ 6BP 52 35 48 9 69 3 50 6 55
-6BP/ 6BP 13 7 10 0 0 2 33 4 36
Unknown 4 3 1
TS-50UTR 0.25
3R/3R 43 30 39 4 31 1 17 8 73
2R/3R 46 34 45 7 54 3 50 3 27
2R/2R 16 12 16 2 15 2 33 0 0
2/4 1 1
GSTP1-105 0.61
Val/Val 10 7 9 1 7 1 17 1 9
Ile/Val 47 35 46 6 43 4 67 3 27
Ile/Ile 49 34 45 7 50 1 17 7 64
GSTT1 1.00
Positive 75 53 72 10 77 4 80 8 73
Negative 27 21 28 3 23 1 20 3 27
Unknown 4 2 1 1
GSTM1 0.14
Positive 54 39 53 9 69 4 80 3 27
Negative 48 35 47 4 31 1 20 8 73
Unknown 4 2 1 1
GSTP¼glutathione S-transferase; TS¼thymidylate synthase; UTR¼untranslated region. *P-value is based on Fisher’s exact test.
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gender with TS-50UTR where more females had the 3R/3R
genotype (P¼0.031); number of metastatic sites with XPA-50
(P¼0.015) and TS-30UTR (P¼0.046); and ECOG performance
status and XRCC1-399 (P¼0.009).
Demographic, clinical, and pathological characteristics and
clinical outcome
With a median follow-up of 11.4 months (range: 3.3–30.9 months)
for the 106 patients of the study, the median survival time was 10.2
months (95% CI: 7.0, 13.2 months). The median time to
progression was 4.7 months (95% CI: 4.2, 5.9 months).
Age, ethnicity, and sex were not associated with patient survival.
Performance status was significantly associated with survival, with
patients with a performance status ECOG¼2 showing an increased
risk of dying of 3.46 (95% CI: 1.99, 6.01; Po0.001) when compared
to those with (ECOG 0-1) upon protocol entry. Patients with a
right-sided tumour tended to have an increased risk of dying
sooner (RR¼1.55, P¼0.077, Table 3) if compared to left-sided
tumours, while the 16 patients with a poorly differentiated tumour
also tended to have a shorter survival (P¼0.058). Bootstrap
analysis confirmed that ECOG status was selected by over 99% of
the bootstrap samples as the only baseline prognostic variable
significantly associated with survival.
In addition, patients with a performance status ECOG¼2
showed an increased risk of progressing, of 2.15 (95% CI: 1.30,
3.57; P¼0.001) when compared with patients who showed a
superior performance status (ECOG 0–1) upon protocol entry.
Age, ethnicity, sex, tumour histologic grade, and side of tumour
were not associated with time to progression in this series of
patients.
Association between the genetic polymorphisms and
survival
By univariate analysis, the XPD-751, ERCC1-118, and GSTP1-105
polymorphisms were significantly associated with survival among
study participants (Table 4). Bootstrap analysis confirmed that
ERCC1-118, GSTP1-105, and XPD-751 were selected by over half of
the bootstrap samples (68–73%) as polymorphisms significantly
associated with survival.
XPD-751 In all, 40 patients (38%) possessed the XPD-751 Lys/Lys
genotype, 13 (12%) showed the XPD-751 Gln/Gln genotype, and 53
(50%) patients were heterozygous for this variant. Using the XPD-
751 Lys/Lys group as a reference the Gln/Gln group showed a 2.44-
fold (95% CI: 1.09, 5.44) increased risk of dying, whereas patients
with the heterozygous genotype showed an intermediate relative
risk of 1.87 (95% CI: 1.06, 3.31) (P¼0.049).
Table 3 Association between clinical and pathological characteristics of study participants and survival and progression after 5-FU/oxaliplatin
chemotherapy
Survival Progression
a
Factors No. of patients Relative risk of dying
b and 95% CI P-value
c Relative risk of progression
a and 95% CI P-value
c
Age (years) 0.70 0.54
460 50 1 1
51–60 26 1.27 (0.69, 2.35) 1.03 (0.60, 1.77)
p50 30 1.16 (0.64, 2.08) 1.30 (0.79, 2.13)
Gender 0.72 0.50
Male 79 1 1
Female 27 1.10 (0.65, 1.87) 0.84 (0.51, 1.40)
Ethnicity 0.26 0.56
Caucasian 75 1 1
Hispanic 14 0.65 (0.30, 1.38) 1.00 (0.51, 1.97)
Black 6 0.46 (0.14, 1.47) 0.70 (0.25, 1.96)
Asian 11 0.55 (0.20, 1.52) 1.47 (0.75, 2.90)
Histology 0.058 0.69
Moderate/well 77 1 1
Poor 16 1.85 (0.93, 3.66) 1.13 (0.61, 2.11)
Unknown 13
Side of tumour 0.077 0.51
Left 71 1 1
Right 34 1.55 (0.93, 2.60) 1.16 (0.74, 1.82)
Unknown 1
Number of metastatic sites 0.95 0.60
14 6 1 1
2 41 0.94 (0.57, 1.63) 0.81 (0.51, 1.30)
3+ 19 0.91 (0.46, 1.78) 0.79 (0.43, 1.47)
Performance status o0.001 0.001
0–1 78 1 1
2 28 3.46 (1.99, 6.01) 2.15 (1.30, 3.57)
5-FU¼5-fluorouracil; CI¼confidence interval.
aTime to progression was calculated from the time that patient started treatment until the patient was taken off study. If the
relative risk is greater than 1, the relative risk can be thought as the average increased risk of progression at any point in time compared to the reference group. The group with
the ratio equal to 1 is the reference group.
bIf the relative risk is greater than 1, the relative risk can be thought as the average increased risk of dying at any point in time
compared to the reference group. The group with the ratio equal to 1 is the reference group.
cP-value based on log-rank test.
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genotype demonstrated a 2.96-fold (95% CI: 1.15, 7.61) increased
risk of dying if compared with the GSTP1-105 Val/Val group.
Patients with a GSTP1-105 Val/Ile genotype showed a 1.82 increase
in risk of dying (95% CI: 0.71, 4.66) (P¼0.019) compared to those
with the Ile/Ile genotype. The GSTP1-105 genotype distribution
was as follows: 49 (46%) GSTP1-105 Ile/Ile, 47 (44%) Val/Ile, and
10 (9%) Val/Val.
ERCC1-118 In terms of the ERCC1-118 polymorphism, patients
with a C/C genotype showed the most favourable survival. Patients
whose tumours were identified with a CT substitution for both
alleles demonstrated a relative risk of dying of 1.86 (95% CI: 0.91,
3.83) compared to patients with the C/C genotype, whereas the
heterozygous patients showed a 2.29-fold (95% CI: 1.19, 4.41)
increase in risk (P¼0.021). The majority of patients (45, 42%)
possessed the heterozygous genotype, 30 patients (28%) showed no
C-T substitution, and 31 patients (29%) demonstrated a
replacement of C by T for both alleles. For the subsequent
multivariable analyses, the patients with the T/T and C/T
genotypes were combined and compared to the patients with the
C/C genotype, for reasons of parsimony and to preserve
monotonicity, since in this series there was no evidence of a
difference between the T/T and C/T genotypes.
Table 4 Association between polymorphisms in the genes of TS, ERCC1, XPD, XPA, XRCC1, GSTP1, GSTT1, and GSTM1 and survival and progression
after 5-FU/oxaliplatin chemotherapy
Survival Progression
a
Factors No. of patients Relative risk of dying
b and 95% CI P-value
c Relative risk of progression
a and 95% CI P-value
c
XPD-751 0.049 0.76
Lys/Lys 40 1 1
Lys/Gln 53 1.87 (1.06, 3.31) 1.13 (0.72, 1.78)
Gln/Gln 13 2.44 (1.09, 5.44) 1.25 (0.59, 2.67)
XPD-156 0.88 0.64
A/A 14 1 1
C/A 59 1.22 (0.55, 2.75) 0.81 (0.44, 1.49)
C/C 30 1.18 (0.49, 2.82) 0.73 (0.36, 1.48)
Unknown 3
XPA-50 0.76 0.61
G/G 24 1 1
A/G 53 0.88 (0.47, 1.62) 1.24 (0.70, 2.18)
A/A 16 1.13 (0.49, 2.45) 1.37 (0.66, 2.84)
Unknown 13
ERCC1-118 0.021 0.51
C/C 30 1 1
C/T 45 2.29 (1.19, 4.41) 1.24 (0.73, 2.11)
T/T 31 1.86 (0.91, 3.83) 1.36 (0.76, 2.41)
XRCC1-399 0.50 0.97
Arg/Arg 44 1 1
Gln/Arg 51 1.07 (0.63, 1.80) 0.95 (0.60, 1.51)
Gln/Gln 10 1.58 (0.71, 3.55) 0.99 (0.47, 2.09)
Unknown 1
TS-30UTR 0.72 0.22
+6BP/+6BP 37 1 1
+6BP/ 6BP 52 1.23 (0.70, 2.15) 1.49 (0.92, 2.40)
-6BP/ 6BP 13 1.18 (0.52, 2.66) 1.39 (0.70, 2.75)
Unknown 4
TS-50UTR 0.42 0.44
3R/3R 43 1 1
2R/3R 46 0.82 (0.49, 1.39) 0.78 (0.48, 1.26)
2R/2R 16 1.32 (0.64, 2.75) 1.06 (0.55, 2.02)
2/4 1
GSTP1-105 0.019 0.011
Val/Val 10 1 1
Ile/Val 47 1.82 (0.71, 4.66) 1.22 (0.56, 2.67)
Ile/Ile 49 2.96 (1.15, 7.61) 2.13 (0.95, 4.76)
GSTT1 0.29 0.93
Positive 75 1 1
Negative 27 1.33 (0.78, 2.28) 0.98 (0.60, 1.60)
Unknown 4
GSTM1 0.59 0.58
Positive 54 1 1
Negative 48 1.14 (0.69, 1.88) 1.13 (0.72, 1.76)
Unknown 4
5-FU¼5-fluorouracil; CI¼confidence interval; GSTP¼glutathione S-transferase; TS¼thymidylate synthase; UTR¼untranslated region.
aTime to progression was calculated
from the time that patient started treatment until the patient was taken off study. If the relative risk is greater than 1, the relative risk can be thought as the average increased risk
of progression at any point in time compared to the reference group. The group with the ratio equal to 1 is the reference group.
bIf the relative risk is greater than 1, the relative
risk can be thought as the average increased risk of dying at any point in time compared to the reference group. The group with the ratio equal to 1 is the reference group.
cP-value based on log-rank test.
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associated with survival in the univariate analysis. Nonetheless,
because TS gene expression is known to be an important predictor
of outcome for patients with colorectal cancer receiving 5-FU-
based therapy, the TS polymorphisms at two sites were included in
the initial multivariable model. The TS-50UTR polymorphism
displayed no association with survival or time to progression, with
TS-30UTR in the Cox model. However, when all four polymorph-
isms XPD-751, ERCC1-118, TS-30UTR, and GSTP1-105 were
stratified by performance status and analysed jointly in the
multivariable analysis, TS-30UTR was weakly associated with
survival. A decision was made to include TS-30UTR in the final
model since it remained strongly associated with time to
progression (Table 5) and because of its potential role in 5-FU
action. As with ERCC1, the two genotypes ( 6BP/ 6BP and
þ6BP/ 6BP) were grouped for reasons of parsimony and to
preserve monotonicity, because of the lack of evidence of any
difference.
The analyses of the polymorphisms for XPD-156, GSTT1,
GSTM1, XRCC1-399, XPA-50, and TS-50UTR did not show
significant associations between overall survival or disease
progression (Table 4).
Combined analysis XPD-751, ERCC1-118, GSTP1-105, and
TS-30UTR for survival
When XPD-751, ERCC1-118, TS-30UTR, and GSTP1-105 were
analysed jointly, stratified by ECOG performance status, XPD-751
and ERCC1-118 remained significantly associated with survival
(Po0.05, see Table 5) and the associations of TS-30UTR and
GSTP1-105 were borderline (0.05oPo0.10). Bootstrap analysis
confirmed that polymorphisms were selected for the final multi-
variable model in 46% for TS 30 UTR, 52% for GSTP1-105, 62% for
ERCC1-118, and 72% for XPD-751. Overall, the bootstrap analysis
confirmed the selection of polymorphisms in the original final
model.
Based on these observations, we performed a second analysis to
elucidate whether a pattern of favourable genotypes could be used
to determine clearcut differences of clinical outcome. For this, a
favourable genotype for each polymorphism was identified and
compared with the group of the remaining two unfavourable
genotypes of that polymorphism. In all, 25 patients had no
favourable polymorphisms, 48 patients had one favourable
polymorphisms, 21 patients had exactly two, and eight patients
had three favourable polymorphisms. Among the four patients
with a missing TS-30UTR assessment, one had two favourable
polymorphisms and was included in the group of patients having
2þ favourable polymorphisms. In this analysis, patients who
possessed two or more favourable genotypes survived a median of
17.4 months (95% CI: 9.4, 26.5) compared to patients who had no
favourable genotypes and had a median survival of only 5.4
months (95% CI: 4.3, 6.0). Patients with one favourable genotype
showed an intermediate median survival time of 10.2 months (95%
CI: 6.8, 15.3) (Po0.001). Using the group of patients with two or
more favourable polymorphisms as the reference group, the
relative risk of dying was 2.14 (95% CI: 1.09, 4.22) and 3.75 (95%
CI: 1.78, 7.89) for patients with only one or 0 favourable
polymorphisms, respectively (Table 6; Figure 1).
Association between time to progression and TS-30UTR,
GSTP1-105 polymorphisms
In the univariate analysis, a dose-dependent association was
observed for the GSTP1-105 polymorphism, demonstrating a
decreased risk of progressing for patients possessing two or one
GSTP1-105 Val alleles (P¼0.011). Using the GSTP1-105 Val/Val
carriers as reference, individuals with a GSTP1-105 Ile/Ile genotype
demonstrated a 2.13-fold (95% CI: 0.95, 4.76) risk for disease
progression. Heterozygotes had an intermediate risk of progres-
sing (relative risk of 1.22 (95% CI: 0.56, 2.67). Patients with one or
two  6BP alleles of the TS-30UTR genotype appeared to have a
higher risk of progressing comparing to the þ6BP/þ6BP
homozygotes, although this association did not reach statistical
significance in the univariate analysis (P¼0.22) (Table 4).
In the multivariate analysis, stratifying by performance status,
the relative risk for progression was 1.76 (95% CI: 1.08, 2.86) for
the TS-30UTR þ6BP/ 6BP and  6BP/ 6BP genotypes combined,
when compared to patients with the þ6BP/þ6BP genotype
(P¼0.020). Using the GSTP1-105 Val/Val genotypes as reference,
patients with GSTP1-105 Val/Ile genotype demonstrated a relative
Table 5 Joint association of XPD-751, ERCC1-118, TS-30UTR, and GSTP1-105 polymorphisms with survival and time to progression after 5-FU/
oxaliplatin chemotherapy for disseminated colorectal cancer (multivariable analysis, stratified by ECOG)
Survival Progression
Factors No. of patients Adj. relative risk
a Adj. P-value
a Adj. relative risk
b Adj. P-value
b
XPD-751 0.037
Lys/Lys 40 1
Lys/Gln 53 1.50 (0.79, 2.87)
Gln/Gln 13 3.33 (1.39, 7.99)
ERCC1-118 0.037
Favourable: C/C 30 1
Unfavourable 76 2.05 (1.00, 4.20)
TS-30UTR 0.091 0.020
Favourable: +6BP/+6BP 37 1 1
Unfavourable 65 1.65 (0.91, 2.99) 1.76 (1.08, 2.86)
Unknown 4
GSTP1-105 0.072 0.018
Val/Val 10 1 1
Ile/Val 47 2.73 (0.88, 8.45) 0.96 (0.42, 2.21)
Ile/Ile 49 3.25 (1.04, 10.16) 2.00 (0.85, 4.71)
5-FU¼5-fluorouracil; CI¼confidence interval; GSTP¼glutathione S-transferase; TS¼thymidylate synthase; UTR¼untranslated region.
aBased on Cox’s proportional-hazards
model, stratified by ECOG, with all four genes included for survival.
bBased on Cox’s proportional-hazards model, stratified by ECOG, with TS-30UTR and GSTP1-105 for time to
progression.
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srisk of 0.96 (95% CI: 0.42, 2.21). The risk of disease progression for
the GSTP1-105 Ile/Ile genotype was 2.00 (95% CI: 0.85, 4.71)
compared to the risk of the GSTP1-105 Val/Val genotype
(P¼0.018).
DISCUSSION
In the current study, we have attempted to move beyond single
gene polymorphisms to a more comprehensive pathway evaluation
to identify genomic variants and patterns that may help predict
clinical response and overall survival to platinum-based che-
motherapy, thus ultimately leading to a more tailored approach to
chemotherapy. Polymorphisms in the genes of GSTP1, ERCC1,
XPD, and TS were associated with overall survival in patients with
refractory advanced colorectal cancer who received 5-FU/oxali-
platin combination chemotherapy. Combination of favourable
genotypes of these polymorphisms identified those patients who
would gain the greatest survival benefit from 5-FU/oxaliplatin
combination chemotherapy. In addition, the GSTP1 (univariate
and multivariate analysis) and TS 30-UTR (multivariate analysis)
gene variants were associated with time to progression. Unfortu-
nately, the low number of clinical responses in our cohort (nine
out of 101 evaluable patients) limited analysis between clinical
response and gene polymorphisms. However, we were able to
perform time to progression analyses that may also be used as
measures of chemotherapy effectiveness.
In vitro reports provide strong evidence that activity of
members of the NER pathway, especially ERCC1, is important
for the removal of DNA adducts caused by platinum compounds
(Reed, 1998). ERCC1 is a highly conserved protein and its role is
critical in DNA-damage recognition and DNA-strand incision. An
analysis by Yu et al (1997) has identified a common C-T
polymorphism at codon 118 of the ERCC1 gene, which results in
the same amino-acid asparagine. Preliminary data by Park et al
(2002) in colon tumours demonstrated a trend towards higher
ERCC1 mRNA levels as the number of T alleles increased. Since
increased gene expression of ERCC1 can lead to platinum
resistance, survival benefit of C/C carriers in the current study
may support these findings. However, the mechanism for this is
unclear. In fact, this silent polymorphism is not part of any known
regulatory binding site. Furthermore, other expression analysis in
ovarian cancer cell lines do not confirm these results (Yu et al,
2000).
The association between the ERCC1 polymorphism and overall
survival in our study was not linear. One possible explanation is
that the polymorphism might be in linkage disequilibrium with
another factor influencing survival to platinum-based chemother-
apy within the same gene or a gene nearby, such as XPD or XRCC1.
This effect might over-ride an alteration of ERCC1 gene expression
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Figure 1 Favourable genomic polymorphism and overall survival (n¼103).
Table 6 Combined analysis of association between XPD-751, ERCC1-118, TS-30UTR and GSTP1-105 polymorphisms and survival after 5-FU/oxaliplatin
chemotherapy for disseminated colorectal cancer
Number of favourable polymorphisms
a Patients (N¼103)
b Relative risk (95% CI) Median survival (95% CI) P-value
c
Lys/Lys, C/C, Val/Val, +6BP/+6BP o0.001
X2 30 1 17.4 months (9.4, 26.5)
1 48 2.14 (1.09, 4.22) 10.2 months (6.8, 15.3)
0 25 3.75 (1.78, 7.89) 5.4 months (4.3, 6.0)
Unknown 3
5-FU¼5-fluorouracil; CI¼confidence interval; GSTP¼glutathione S-transferase; TS¼thymidylate synthase; UTR¼untranslated region.
aFavourable genotypes of XPD-751
(Lys/Lys), ERCC1-118 (C/C), GSTP1-105 (Val/Val), and TS-30UTR (+6BP/+6BP) polymorphisms.
bCombined analysis was performed for only 103 out of 106 patients. Among the
four patients with a missing data of the TS-30UTR polymorphism, one patient was included since the patient had two favourable polymorphisms (ERCC1-118 and GSTP1-105).
cBased on log-rank test.
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the numbers of patients included in this series, this lack of
monotonicity occurred by chance alone; analysis with an
independent data set will be necessary to better characterise this
association.
Another essential member of the NER pathway is the XPD gene,
otherwise known as ERCC2 (Sung et al, 1993). Reports have shown
that common polymorphisms in the XPD gene may be associated
with differential DNA repair capacity (Dybdahl et al, 1999; Lunn
et al, 2000; Spitz et al, 2001). Interestingly, studies with regard to
the polymorphisms’ impact on DNA repair capacity have yielded
diverging results (Dybdahl et al, 1999; Lunn et al, 2000; Spitz et al,
2001; Chen et al, 2002). Recently, preliminary results from our
group supported the hypothesis that the 751Lys allele may be
associated with an impaired NER efficacy (Park et al, 2001). The
current data indirectly confirm this hypothesis, since patients who
possess one or two 751Gln alleles benefited less from platinum-
based chemotherapy compared to 751Lys carriers. Although it has
been posited that the proximity of the substituted polar amino acid
to the poly(A) signal may be affect XPD protein function (Dybdahl
et al, 1999), the molecular mechanism by which this polymorph-
ism alters the efficacy of oxaliplatin in tumour cells remains
unknown. A second polymorphism in ERCC2 (XPD-156) and other
members of the DNA repair pathway (XPA-5 and XRCC1-399)
were not found to be associated with clinical outcome.
The purpose of this study was to evaluate the impact of genomic
variations on different mechanisms that alter drug efficacy. Besides
changes in DNA-repair function, the rate of inactivation of the
administrated drug compound may also determine its efficacy in
the tumour tissue. The GST superfamily participates in the
detoxification processes of platinum compounds (Ban et al,
1996; Goto et al, 1999). We have recently reported that the GSTP1
polymorphism at codon 105 may be associated with superior
overall survival in colorectal cancer patients (Stoehlmacher et al,
2002). The current study identifies this GSTP1-105Val variant as a
predictor for time to progression to 5-FU/oxaliplatin, as well as
overall survival.
Earlier reports in human tissues demonstrated a decline in
GSTP1 activity with an increasing number of GSTP1-105Val alleles
(Watson et al, 1998). Our data suggest that patients with the Val
allele might experience protracted detoxification of oxaliplatin.
Thus, a prolonged exposure of the tumour to oxaliplatin may lead
to an increased overall efficacy of the drug and a superior survival.
On the other hand, the deletion polymorphisms of GSTT1, and
the GSTM1, which are associated with abolished enzyme activity
(London et al, 2000), were not associated with clinical outcome.
Predominant expression of the GSTP1 subclass (compared to
GSTT1 and GSTM1) in colorectal epithelial and tumour tissue may
explain in part this phenomenon (Moscow et al, 1989).
Analyses of polymorphisms in genes of DNA-repair and phase II
metabolising enzymes focused on the oxaliplatin effect. Modifica-
tions of 5-FU efficacy were also evaluated by analysing genomic
variants in the gene of its target molecule TS. Two common
polymorphic sites within the TS gene that might alter expression
levels have been described (Horie et al, 1995; Ulrich et al, 2000).
Although there have been reports of four, five, and nine repeats
within certain African and Asian populations (Luo et al, 2002;
Marsh et al, 2000), the majority of individuals possesses either two
repeats (2R) or three repeats (3R) of a 28-bp sequence.
We hypothesised that the 50-TS polymorphism maybe predictive
for clinical outcome in patients of the current study. This
polymorphism was not associated with overall survival or time
to progression in our cohort. One reason for this lack of prediction
may be the fact that these patients received combination
chemotherapy. Second, a genomic polymorphism represents a
static value unable to change in response to a new situation in the
tumour cell (e.g. changes in oxygen supply, chemotherapy) as it
would be reflected by expression levels. Thus, a strong impact of
the genomic variation on functionality is needed to keep the power
of prediction, especially when other confounders (e.g. previous
and combination chemotherapy) are present. Although several
reports have consistently revealed an association of the 50-TS
polymorphism and clinical outcome to 5-FU, a sizeable fraction of
patients with the triple repeat genotype in those studies showed
low TS expression or some short-term benefit to 5-FU chemother-
apy (Iacopetta et al, 2001; Pullarkat et al, 2001), thus indicating the
limitations of the predictive strength of this polymorphism. Other
factors (e.g. transcriptional factors, LOH in the tumour) may in
addition alter the expression, and this influence cannot be
accurately reflected by a genotype analysis. Most recently, our
group has identified a novel single-nucleotide polymorphic change
within the 50-TS tandem repeat within the USF-1 consensus
element that abolishes USF-1 binding and alters transcriptional
activation (Mandola et al, 2003). The clinical implication of this
finding is unclear at this time. We are currently engaged in a
prospective confirmatory study in refractory colorectal cancer
patients under platinum-based therapy where the 50-TS tandem
repeat is analysed in the context of this novel polymorphism.
At the moment, less information is available with regard to a
recently identified 6-bp deletion polymorphism in the 30UTR of the
TS gene. This polymorphism might alter mRNA stability, its
secondary structure, or expression as it has been demonstrated for
alterations of the 30-region in other genes (Gou et al, 1998;
Rajagopalan and Malter, 2000). Preliminary data show that the TS-
30 UTR polymorphism may be correlated with differential TS gene
expression, with 6-bp deletions leading to lower intratumoral TS
mRNA (Lenz et al, 2002a). In our study, however, patients who
possessed the deletion on one or both chromosomes were at a
higher relative risk of dying and disease progression after
stratification by performance status. We have no compelling
mechanistic explanation for this finding at this time.
Nevertheless, these data suggest that this polymorphism maybe
associated with TS functionality. Further biochemical analyses are
needed to explore the significance of this polymorphism for TS
function. In addition, it would be helpful to perform haplotype
analyses of both TS polymorphisms in order to determine possible
opposing or synergistic effects of these polymorphisms on TS
expression and clinical outcome. The association between TS-50
and TS-30 polymorphisms, although significant (P¼0.037, Pear-
son’s w
2 test), did not reveal a clear pattern in our cohort.
Since the time of our analysis presented in the current report,
and previously in abstract form (Lenz et al, 2002b), preliminary
data from the first large-scale prospective pharmacogenetic study
in colorectal cancer was recently presented. The aim of the study
was to validate previously reported correlations between the
various genomic polymorphisms (including several included in
this report) and clinical response and toxicity. The pharmacoge-
netic element was added midway to a phase III GI intergroup trial
(N9741) comparing three regimens for first-line therapy in
metastatic colorectal cancer. In all, 18 genetic variants in 11 genes
were assessed. The XPD751Gln genotype was associated with
decreased clinical response to oxaliplatin-based regimen. This is
consistent to our previously reported clinical correlation. Further-
more, the TS-30UTR polymorphism was also found to be
associated with clinical response and time to progression, GST
polymorphisms were not associated with clinical response, and
ERCC1-118 polymorphism was not evaluated. No data on overall
survival were available at the time of abstract presentation
(McLeod et al, 2003).
Significant differences in patient selection (initial metastatic vs
refractory colorectal cancer), treatment schedules, and other
factors exist between the two studies, which may or may not have
contributed to the consistent or discordant results. Moreover, the
N9741 pharmacogenetic data are available only in preliminary
form at this time, making meaningful discussion or comparison of
the data difficult. Still, these preliminary results underscore the
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clinical outcome to a given chemotherapeutic regimen. This would
be especially useful now that we are at a juncture where equivalent
chemotherapeutic regimens with differing mechanisms of action
are available for the treatment of advanced colorectal cancer
(Tournigand et al, 2004).
To conclude, this pilot study demonstrates that a combined
genotype analysis of GSTP1-105, TS-30UTR, ERCC1-118, and XPD-
751 may contribute to the selection of patients who would benefit
from 5-FU/oxaliplatin chemotherapy. Our study is limited by its
retrospective nature with a relatively small sample size compared
to the total number of patients treated in the protocol. As stated
before, the small number of responses did not allow for the
identification of predictors of response, although predictors of
time to progression were identified. To our knowledge, this is the
first study that identifies a pharmacogenetic profile that may
predict clinical outcome to platinum-based chemotherapy in
advanced colorectal cancer. The resampling analysis suggests that
the current study has internal validity, that is, others analysing the
number of favourable polymorphisms would reach the same
conclusions, and that this approach has potential and merits
further investigation.
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